Filter by tags: Europe Radiopharmaceutical Clear all tag filters
5 news articles found
Rosatom has begun construction of a new plant for the production of medical isotope products at the Karpov Scientific Research Institute of Physics & Chemistry in Obninsk, Kaluga region. The plant will produce a wide range of radiopharmaceuticals including those based on iodine-131, samarium-153, and molybdenum-99 isotopes. It will also develop promising active radiopharmaceuticals based on lutetium-177, actinium-225, radium-223 and other isotopes. Once completed, in 2025, it will be the largest such facility in Europe, Rosatom says. It will operate in accordance with international GMP (good manufacturing practice) standards.
- Source: NEI Magazine
- Date: Friday, 27 January 2023
- Original article: neimagazine.com/news/newsrosatom-begins-construction-of-radiopharmaceuticals-plant-10546229
The aim is to have production lines operating at the plant in Obninsk by 2025, supplying products for the diagnosis and treatment of patients, including a wide range of cancers. Rosatom says it will ensure Russia's sovereignty in the production of radiopharmaceuticals.
- Source: World Nuclear News
- Date: Wednesday, 25 January 2023
- Original article: world-nuclear-news.org/Articles/Construction-starts-for-Russian-medical-isotopes-p
The nuclear medicine sector is a small part of the wider nuclear industry, but it provides some of the most pioneering technologies in healthcare - and is close to making personalised medicine a reality. Antonis Kalemis, president of Nuclear Medicine Europe and business manager for molecular imaging at Siemens Healthineers, describes how nuclear medicine also tackles the most trenchant condition in modern healthcare: cancer.
- Source: World Nuclear News
- Date: Thursday, 29 July 2021
- Original article: world-nuclear-news.org/Articles/Viewpoint-Nuclear-medicine-is-crucial-for-fighting
Foratom said in a joint position paper with Nuclear Medicine Europe that EU policy makers should find ways of promoting new research reactor capacity along with innovation in the sector, and implement a number of recommendations to maintain the current level of medical radioisotopes supply.
According to the paper, in order to ensure that the supply of medical radioisotopes will be continued, the EU needs to develop a “robust” supply chain which goes beyond irradiation, adapt clinical research and development of new radiopharmaceutical compounds, and reconsider reimbursement systems for radiopharmaceutical products.
- Source: Nucnet
- Date: Wednesday, 16 June 2021
- Original article: nucnet.org/news/foratom-urges-european-union-to-provide-more-support-for-nuclear-medicine-6-2-2021
Europe must take action to maintain the current level of medical radioisotopes supply, according to a joint position paper from Foratom, the European nuclear trade body, and Nuclear Medicine Europe, which represents pharmaceutical and imaging equipment companies in the field of nuclear medicine. They say the European Union should promote new research reactor capacity along with innovation in the sector and the design modification of the current fleet.
- Source: World Nuclear News
- Date: Wednesday, 16 June 2021
- Original article: world-nuclear-news.org/Articles/EU-industry-bodies-call-for-more-support-for-nucle